EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

EnteroBiotix announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.

EnteroBiotix, a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointments of Dr James Barnes as Chief Operating Officer (“COO”) and Chris Lea as Chief Financial Officer (“CFO”).

EnteroBiotix, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director.

Glasgow, Scotland – 27 October 2021 – EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow

Glasgow, Scotland – 7th September 2021 – EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.